CDK4 and breast cancer: Alpelisib plus fulvestrant displayed an overall response rate (ORR) of 19.0% and median progression-free survival (PFS) around 11 months in PIK3CA-mutated HR+ advanced breast cancer patients progressing on or after treatment with CDK4/6i and/or ET [6,54].